J-code information available Click here for more details
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.1
LIBTAYO is indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.1
LIBTAYO is indicated for the first-line treatment of patients with non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is1:
LIBTAYO (cemiplimab-rwlc) Injection is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles.
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light. Do not freeze or shake.
LIBTAYOhcp.com or 1.877.LIBTAYO select option 1.
Regeneron and Sanofi do not recommend the use of any particular distributor or specialty pharmacy.
|How supplied||350-mg/7-mL (50 mg/mL) solution in a single-dose vial|
|Quantity and units per case||1 vial per carton/24 cartons per case|
|NDC||61755-008-01 (350 mg/7 mL)|
|HCPCS codes||J9119 - Injection, cemiplimab-rwlc, 1 mg|
|GTIN||00361755008013 (350-mg/7-mL case)
00361755008018 (350-mg/7-mL carton)
|UPC||361755008018 (350 mg/7 mL)|
|LIBTAYO product information sheet|
|LIBTAYO dosage and immune-mediated adverse reactions (imARs) guide|
Reference: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC.